FDA OKs Merck treatment for babies with HIV

|About: Merck & Co Inc. (MRK)|By:, SA News Editor

The FDA has approved Merck's (MRK -0.9%) Isentress oral formulation for treating HIV-1 infection in babies who are four weeks old and above when used with other therapies, which appears to increase the chances of success.

Merck expects the formulation to be available in the U.S. in Q3. (PR)